News Sentiment

MCRB sentiment intelligence

Seres Therapeutics Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 54 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 6.11 Week of 10 Jul 2026
Weighted tone 54/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Market update

80/100 classification confidence.

Company focus 49

directly relevant articles

Source quality 2

high-authority source matches

Trend context Trend inactive

-21.1% over one week, +7.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Neutral

Seres Therapeutics (MCRB) awards 6,500-share stock option grant to director Dere

Market Reaction

Price moving ahead of tone

63/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Market update 80/100 classification
One-week reaction -21.1% Price reacting lower
Trend fit Trend inactive 7.2% over four weeks
Fair value -69.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 40
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 49
Industry context 8
Sector context 0

Sources

Coverage mix

Publishers
Stock Titan 18
Market source 6
TradingView 5
GlobeNewswire 5
simplywall.st 3
Quartr 2
Moomoo 2
Investing.com Nigeria 1

Event Lens

What the news is about

Classified themes
Market update 32
Earnings 18
Regulatory and legal 3
Analyst action 2
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 57
Stock Titan Direct company coverage

Seres Therapeutics (MCRB) awards 50,000 stock options to director-officer

Seres Therapeutics (MCRB) has granted director and officer Richard N. Kender 50,000 stock options at an exercise price of $9.13 per share. These options will vest in 36 equal monthly installments beginning March 2, 2026, and are set to expire on March 3, 2036. Following this tran

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

[Form 4] Seres Therapeutics, Inc. Insider Trading Activity

Seres Therapeutics, Inc. reported an insider trading activity where officer Brady Kelly received a grant of stock options for 18,750 shares at an exercise price of $9.13 per share. These options will vest over time, with 25% vesting on March 2, 2027, and the remainder in quarterl

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Seres Therapeutics (MCRB) awards 25,000-share stock option grant to officer Henn

Seres Therapeutics (MCRB) has granted Matthew R. Henn, an officer, 25,000 stock options with an exercise price of $9.13 per share, expiring on March 3, 2036. The options will vest 25% on March 2, 2027, with the remainder vesting in 12 equal quarterly installments, contingent on c

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:39
Source
Stock Titan
Stock Titan Direct company coverage

Seres Therapeutics (MCRB) director Kurt Graves receives 6,500 stock options at $7.14

Seres Therapeutics, Inc. director Kurt Graves was granted 6,500 stock options at an exercise price of $7.14 per share, expiring on July 7, 2036. These options will vest on the earlier of July 8, 2027, or the day before the first annual meeting after July 8, 2026, linking the comp

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:39
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 4 Seres Therapeutics Inc For: 10 July By Investing.com

This article reports on a Form 4 filing for Seres Therapeutics Inc. (MCRB) dated July 10. Such filings typically disclose transactions by company insiders, and this particular report indicates activity for Seres Therapeutics on that date. The article is brief and primarily serves

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:39
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Seres Therapeutics (MCRB) awards director Eric Shaff 6,500 stock options at $7.14

Seres Therapeutics director Eric D. Shaff was granted 6,500 stock options at an exercise price of $7.14 per share, expiring on July 7, 2036. The options will vest on the earlier of July 8, 2027, or the day before the first annual stockholder meeting after July 8, 2026. This grant

Tone
Neutral 50/100
Event
Market update
Published
10 Jul 2026 20:39
Source
Stock Titan
Quartr Direct company coverage

Seres Therapeutics (MCRB) H.C. Wainwright 4th Annual BioConnect Investor Conference summary

Seres Therapeutics presented at the H.C. Wainwright 4th Annual BioConnect Investor Conference, highlighting its novel drug technology, the first FDA-approved oral microbiome drug with an 88% sustained response for C. difficile recurrence, and the integration of generative AI into

Tone
Positive 65/100
Event
Market update
Published
09 Jul 2026 06:39
Source
Quartr
Stock Titan Direct company coverage

Seres Therapeutics (NASDAQ: MCRB) investors back 900,000-share 2025 incentive plan increase

Seres Therapeutics, Inc. (NASDAQ: MCRB) shareholders approved all proposals at their reconvened 2026 Annual Meeting, including a significant increase of 900,000 shares to the 2025 Incentive Award Plan. This move aims to allow continued equity-based compensation. Other key approva

Tone
Neutral 50/100
Event
Market update
Published
08 Jul 2026 20:11
Source
Stock Titan
Quartr Direct company coverage

Seres Therapeutics (MCRB) Q4 2025 earnings summary

Seres Therapeutics (MCRB) reported a net income of $5.7 million for 2025, a significant improvement from a $125.8 million net loss in 2024, primarily due to lower operating expenses and the VOWST sale. The company is prioritizing live biotherapeutic programs, especially SER-603 f

Tone
Positive 71/100
Event
Earnings
Published
08 Jul 2026 20:11
Source
Quartr
Market source Direct company coverage

Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment

Seres Therapeutics announced early clinical data indicating SER-155's potential to treat immune checkpoint inhibitor-related enterocolitis (irEC) without systemic immunosuppression. The investigator-sponsored trial showed that 80% of patients achieved an immunosuppressive-free cl

Tone
Positive 81/100
Event
Market update
Published
08 Jul 2026 18:39
Source
Market source
Benzinga Direct company coverage

Why Is Seres Therapeutics Stock Falling Today? - Seres Therapeutics (NASDAQ:MCRB)

Seres Therapeutics (NASDAQ:MCRB) stock is down today despite the company posting early positive data for its cancer therapy complication treatment, SER-155. The investigational drug, designed to treat immune-related enterocolitis (irEC), showed promising results in an investigato

Tone
Negative 38/100
Event
Regulatory and legal
Published
08 Jul 2026 17:11
Source
Benzinga
Seeking Alpha Direct company coverage

Seres Therapeutics, Inc. (MCRB) Discusses Promising SER-155 Clinical Trial Results for Immune Checkpoint Inhibitor Related Andropilatis - Slideshow (NASDAQ:MCRB) 2026-07-08

Seres Therapeutics, Inc. (MCRB) released a slide deck discussing promising clinical trial results for its drug SER-155. The trials focus on treating immune checkpoint inhibitor related andropilatis. This information was published by SA Transcripts on Seeking Alpha.

Tone
Positive 72/100
Event
Earnings
Published
08 Jul 2026 17:00
Source
Seeking Alpha
Moomoo Direct company coverage

Seres Therapeutics' Phase 1 Trial of SER-155 Meets Primary Endpoint; Shares Rise Pre-Bell

Seres Therapeutics announced that its Phase 1 clinical trial of SER-155, an investigational microbiome therapeutic, met its primary endpoint for safety and tolerability in patients undergoing allogeneic hematopoietic stem cell transplantation. The trial also demonstrated evidence

Tone
Positive 71/100
Event
Regulatory and legal
Published
08 Jul 2026 13:11
Source
Moomoo
grafa.com Direct company coverage

Seres Therapeutics reports positive early SER-155 data

Seres Therapeutics announced positive early clinical data for its microbiome candidate SER-155, which showed an 80% immunosuppressive-free clinical response rate and favorable tolerability in a 15-patient study. This investigational treatment aims to modulate the gut microbiome a

Tone
Positive 82/100
Event
Regulatory and legal
Published
08 Jul 2026 13:11
Source
grafa.com
Stock Titan Direct company coverage

Seres drug helped 80% of patients in cancer-therapy gut inflammation trial

Seres Therapeutics announced positive early clinical data for its drug SER-155 in treating immune checkpoint inhibitor-related enterocolitis (irEC), a severe side effect of cancer therapies. In a 15-patient trial, 80% achieved immunosuppressive-free clinical response at Day 15, w

Tone
Negative 33/100
Event
Market update
Published
08 Jul 2026 11:11
Source
Stock Titan
AD HOC NEWS Direct company coverage

Seres Therapeutics outlines its microbiome drug strategy as MCRB works to regain traction

Seres Therapeutics is focusing on microbiome-based treatments, with a lead drug candidate aimed at recurrent infections and other early-stage assets for inflammatory conditions. The company's strategy involves heavy investment in clinical trials and manufacturing, emphasizing the

Tone
Positive 64/100
Event
Market update
Published
07 Jul 2026 13:42
Source
AD HOC NEWS
TradingView Direct company coverage

Price to book forward of Seres Therapeutics, Inc. – NASDAQ:MCRB

This article provides financial information for Seres Therapeutics, Inc. (NASDAQ: MCRB), specifically focusing on its price-to-book forward ratio. It briefly mentions the company's stock market listing on Nasdaq and the market status, which was closed at the time of publication.

Tone
Neutral 50/100
Event
Market update
Published
06 Jul 2026 14:10
Source
TradingView
Finviz Direct company coverage

MCRB - Seres Therapeutics Inc Dividends

This article provides a detailed financial overview of Seres Therapeutics Inc. (MCRB), including its stock performance, key financial metrics, insider and institutional ownership, and analyst recommendations. It highlights various performance indicators and valuation ratios witho

Tone
Neutral 50/100
Event
Analyst action
Published
03 Jul 2026 21:39
Source
Finviz
Stock Titan Direct company coverage

Seres Therapeutics (MCRB) director awarded 7,508 stock options vesting by 2027

Seres Therapeutics director Dennis A. Ausiello was granted 7,508 stock options with an exercise price of $7.94 per share, expiring in 2036. These options vest in four equal quarterly installments beginning October 2026 and are contingent on his continued service as a non-employee

Tone
Neutral 50/100
Event
Market update
Published
03 Jul 2026 03:34
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 4 Seres Therapeutics Inc For: 2 July By Investing.com

This article from Investing.com reports on a Form 4 filing for Seres Therapeutics Inc (MCRB) for July 2nd. The brief post includes various market data for indices, commodities, and bonds, alongside trending and most popular articles on Investing.com. It indicates that the company

Tone
Neutral 50/100
Event
Market update
Published
02 Jul 2026 22:40
Source
Investing.com Canada